Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19986782 | 1.00 | GPR3 (0.44) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL3532632 | 0.76 | GPR3 (0.36) | GPR3KDM4EGLSATMALDH1A1 | |
| SCHEMBL147947 | 0.76 | GLS (0.56) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL30506312 | 0.76 | GLS (0.56) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL14077457 | 0.75 | MEN1 (0.42) | KDM4EATMALDH1A1MAPK1HSD17B10 | |
| SCHEMBL823488 | 0.74 | GSK3B (0.45) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL29461124 | 0.74 | GPR3 (0.44) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL21379983 | 0.74 | GPR3 (0.44) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL31172010 | 0.74 | GPR3 (0.44) | GPR3KDM4EHTR2AHTR2CHTR2B | |
| SCHEMBL5565026 | 0.74 | GPR3 (0.44) | GPR3KDM4EHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | GPR3 3516/4885KDM4E 769/4885HTR2A 2195/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | GPR3 3516/4885KDM4E 769/4885HTR2A 2195/4885 |
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | GPR3 2345/4885KDM4E 2636/4885HTR2A 3182/4885 |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | GPR3 4794/4885KDM4E 872/4885HTR2A 4483/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | GPR3 3516/4885KDM4E 769/4885HTR2A 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.